198 related articles for article (PubMed ID: 19236054)
1. Ubiquitin-family modifications of topoisomerase I in camptothecin-treated human breast cancer cells.
Kanagasabai R; Liu S; Salama S; Yamasaki EF; Zhang L; Greenchurch KB; Snapka RM
Biochemistry; 2009 Apr; 48(14):3176-85. PubMed ID: 19236054
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin, SUMO-1, and UCRP in camptothecin sensitivity and resistance.
Desai SD; Mao Y; Sun M; Li TK; Wu J; Liu LF
Ann N Y Acad Sci; 2000; 922():306-8. PubMed ID: 11193908
[No Abstract] [Full Text] [Related]
3. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff.
Strumberg D; Pilon AA; Smith M; Hickey R; Malkas L; Pommier Y
Mol Cell Biol; 2000 Jun; 20(11):3977-87. PubMed ID: 10805740
[TBL] [Abstract][Full Text] [Related]
4. A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation.
Sun Y; Miller Jenkins LM; Su YP; Nitiss KC; Nitiss JL; Pommier Y
Sci Adv; 2020 Nov; 6(46):. PubMed ID: 33188014
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
6. Conjugation of human topoisomerase 2 alpha with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificity.
Agostinho M; Santos V; Ferreira F; Costa R; Cardoso J; Pinheiro I; Rino J; Jaffray E; Hay RT; Ferreira J
Cancer Res; 2008 Apr; 68(7):2409-18. PubMed ID: 18381449
[TBL] [Abstract][Full Text] [Related]
7. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
8. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
Pondarré C; Strumberg D; Fujimori A; Torres-León R; Pommier Y
Nucleic Acids Res; 1997 Oct; 25(20):4111-6. PubMed ID: 9321666
[TBL] [Abstract][Full Text] [Related]
9. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes.
Desai SD; Zhang H; Rodriguez-Bauman A; Yang JM; Wu X; Gounder MK; Rubin EH; Liu LF
Mol Cell Biol; 2003 Apr; 23(7):2341-50. PubMed ID: 12640119
[TBL] [Abstract][Full Text] [Related]
10. SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin.
Horie K; Tomida A; Sugimoto Y; Yasugi T; Yoshikawa H; Taketani Y; Tsuruo T
Oncogene; 2002 Nov; 21(52):7913-22. PubMed ID: 12439742
[TBL] [Abstract][Full Text] [Related]
11. Differences in the topoisomerase I cleavage complexes formed by camptothecin and wakayin, a DNA-intercalating marine natural product.
Kokoshka JM; Capson TL; Holden JA; Ireland CM; Barrows LR
Anticancer Drugs; 1996 Sep; 7(7):758-65. PubMed ID: 8949987
[TBL] [Abstract][Full Text] [Related]
12. Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.
Shamanna RA; Lu H; Croteau DL; Arora A; Agarwal D; Ball G; Aleskandarany MA; Ellis IO; Pommier Y; Madhusudan S; Bohr VA
Oncotarget; 2016 Mar; 7(12):13269-84. PubMed ID: 26959889
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.
Furuta T; Takemura H; Liao ZY; Aune GJ; Redon C; Sedelnikova OA; Pilch DR; Rogakou EP; Celeste A; Chen HT; Nussenzweig A; Aladjem MI; Bonner WM; Pommier Y
J Biol Chem; 2003 May; 278(22):20303-12. PubMed ID: 12660252
[TBL] [Abstract][Full Text] [Related]
14. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis.
Li XG; Haluska P; Hsiang YH; Bharti AK; Kufe DW; Liu LF; Rubin EH
Biochem Pharmacol; 1997 Apr; 53(7):1019-27. PubMed ID: 9174116
[TBL] [Abstract][Full Text] [Related]
15. The effect of camptothecin on topoisomerase I catalysis.
Christiansen K; Westergaard O
Ann N Y Acad Sci; 1996 Dec; 803():50-9. PubMed ID: 8993500
[TBL] [Abstract][Full Text] [Related]
16. Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin.
Li XG; Haluska P; Hsiang YH; Bharti A; Kufe DW; Rubin EH
Ann N Y Acad Sci; 1996 Dec; 803():111-27. PubMed ID: 8993505
[No Abstract] [Full Text] [Related]
17. SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage.
Mao Y; Sun M; Desai SD; Liu LF
Proc Natl Acad Sci U S A; 2000 Apr; 97(8):4046-51. PubMed ID: 10759568
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of camptothecin.
Liu LF; Desai SD; Li TK; Mao Y; Sun M; Sim SP
Ann N Y Acad Sci; 2000; 922():1-10. PubMed ID: 11193884
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of resistance to camptothecins.
Saleem A; Edwards TK; Rasheed Z; Rubin EH
Ann N Y Acad Sci; 2000; 922():46-55. PubMed ID: 11193924
[TBL] [Abstract][Full Text] [Related]
20. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
